Chronic Inflammation, C-Reactive Protein, Inflammation, Insulin Resistance, Interleukin-6, Metabolic Syndrome, Obesity, Roux en Y Gastric Bypass
Conditions
Keywords
Pentraxin-3 (PTX3), Insulin Resistance, HOMA-IR, C-Reactive Protein (CRP), Bariatric Surgery, Roux-en-Y Gastric Bypass, Metabolic Outcomes, Inflammatory Biomarkers, Predictive Biomarker
Brief summary
This study evaluated the prognostic value of preoperative pentraxin-3 (PTX3) levels in predicting weight loss, inflammatory resolution (CRP, IL-6), and metabolic improvements (HOMA-IR) following Roux-en-Y gastric bypass in patients with obesity.
Detailed description
This single-center longitudinal study was conducted at Istanbul University Hospital. A total of 23 patients undergoing primary Roux-en-Y gastric bypass were included. PTX3 levels were measured preoperatively, and patients were stratified according to a data-derived cut-off (\ 21.7 ng/mL). Outcomes assessed at baseline, 3 months, and 6 months included body weight, BMI, excess weight loss (%EWL), fasting insulin, HOMA-IR, CRP, and IL-6. The primary hypothesis was that preoperative PTX3 would predict postoperative CRP normalization and insulin resistance improvement.
Interventions
OTHERBiomarker Stratification by PTX3
Participants were stratified into groups according to preoperative serum PTX3 levels (≥21.7 ng/mL vs. \<21.7 ng/mL). All participants underwent Roux-en-Y gastric bypass and were prospectively evaluated for metabolic (HOMA-IR, %EWL) and inflammatory (CRP, IL-6) outcomes during 6 months of follow-up.
Sponsors
Istanbul University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Days to 65 Days
Healthy volunteers
No
Inclusion criteria
* Age: 18-65 years * Body mass index (BMI) ≥40 kg/m², or BMI ≥35 kg/m² with obesity-related comorbidity * Eligible for primary Roux-en-Y gastric bypass * Able to provide written informed consent
Exclusion criteria
* Previous bariatric surgery * Severe hepatic, renal, or cardiac failure * Active infection or inflammatory disease * Malignancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in HOMA-IR from baseline to 6 months | Baseline, 3 months, 6 months | Assessment of the improvement in insulin resistance after Roux-en-Y gastric bypass, measured by the homeostasis model assessment of insulin resistance (HOMA-IR). Preoperative PTX3 stratification will be used to evaluate predictive value. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percent Excess Weight Loss (%EWL) at 6 months | 6 months | Evaluation of weight loss outcomes after surgery, calculated as percent excess weight loss (%EWL). Comparisons will be made between PTX3 high vs. low groups. |
| CRP normalization at 6 months | 6 months | Proportion of patients achieving CRP ≤5 mg/L after surgery. Predictive value of baseline PTX3 will be assessed. |
| Change in IL-6 from baseline to 6 months | Baseline, 3 months, 6 months | Change in serum IL-6 levels after surgery, analyzed between PTX3 high vs. low groups. |
Outcome results
None listed